International Clinical Trials

International Clinical Trials specialize in the application of the latest scientific technologies to the pharmaceutical industry.

The technologies possess great sensitivity & specificity that differentiate between sedating and non-sedating agents.

These unique methodologies supersede all current technologies used to evaluate the sedating properties of different drugs.

They can facilitate a label addition establishing superior safety for minimally sedating medications.

These methodologies ensure maximum commercialization of minimally sedating drugs.


According to the World Health Organization schizophrenia is a severe mental disorder that affects around 21 million people worldwide.

This chronic disabling disorder affects around 2.4 million people in the US and 5 million people in the European Union that had a disability-adjusted life years lost (DALY) total of 637,693 in 2010.

Psychoses, including schizophrenia, are categorized by distortions in thinking, language, emotions, perception, sense of self and behaviour.
Frequent psychotic experiences include hallucinations (hearing, seeing or feeling things that are not there) and delusions (fixed false beliefs or suspicions that are inflexibly held even when there is evidence to the contrary).
The disorder often makes it challenging for people affected to work or study normally.
Discrimination and stigma may result in a lack of access to health and social services.
Moreover, individuals with psychosis are at high risk of exposure to human rights violations like long term confinement in institutions.
Schizophrenia usually commences in late adolescence or early adulthood.
Treatment with drugs and psychosocial support is effective.
With suitable treatment and social support, affected people may lead a productive life and can be integrated in society.

The World Health Organization assessed direct costs of schizophrenia in Western countries that ranged from 1.6% to 2.6% of total health care expenditures that translates to between 7% and 12% of the gross national product.

Decision Resources have reported that the schizophrenia market will decline from $6.1 billion in 2016 to $5.1 billion in 2026.


Bipolar disorders affect about 60 million people worldwide.

They affect approximately 5.7 million adults in the US or around 2.6% of the US population aged 18 and older every year according to the National Institute of Mental Health.

A further 3 million people in Europe suffer from these conditions and they had a DALY of 727,841 in 2010.

These conditions usually manifest both manic and depressive episodes separated by periods of normal mood.
Manic episodes are characterised by an elevated or irritable mood, over-activity, pressure of speech, inflated self-esteem and a decreased need for sleep.
People who have manic attacks but do not experience depressive episodes are also categorized as having bipolar disorder.
There are effective treatments available for the treatment of the acute phase of bipolar disorder as well as preventing relapse.
These are drugs available that stabilize mood.
Psychosocial support is a significant component of treatment.


The World Health Organization reports that road accidents claim more than 1.2 million lives each year.

Road traffic injuries are the leading cause of death for the 15-29 year age group and the second most common cause of death for those aged 5-14 years.

There is a strong unmet medical need for medications that are safer for patients who drive cars & operate equipment.

This is because 43% of deceased US road traffic accident victims had drugs and 37% had alcohol found in their bloodstream.

Twenty two percent of patients on anxiolytics, antidepressants, hypnotics, antiepileptics, opioids, sedating antihistamines, hypoglycemic agents, central nervous system (CNS) stimulants, and herbals with CNS-related effects are involved in motor vehicle accidents.

33% of patients suffering from schizophrenia and schizoaffective disorders are involved in car accidents.


Our passionate mission is to find the safest anti-psychotics for patients who drive cars.

The goal is to save lives, reduce severe trauma injuries, property damage and insurance premiums caused by serious motor vehicle accidents.


International Clinical Trials business model is based on partnerships with other pharmaceutical companies that possess minimally sedating antipsychotic compounds.

Commercial returns for low sedating antipsychotic drugs are maximised throughout their whole product life cycle by early clinical trial comparisons with heavily sedating antipsychotic compounds.


Val Schabinsky founded International Clinical Trials in 2005 and has served as director and chairman since incorporation occurred on 24 October 2011.

Previously he worked in various roles in the pharmaceutical industry at Bristol-Myers Squibb & Merck.

He also pioneered the positions of medical product specialist at Janssen-Cilag & medical communications manager at Pfizer.

Prior to this, he was the first person in the world to research the mechanism of acute tolerance to alcohol and obtained four years academic teaching experience in the Department of Pharmacology, University of Sydney.

Val holds a Bachelor of Science and a Master of Science (Pharmacology) degree from the University of Sydney.


Email Us Follow on Twitter

Val Schabinsky

Founder and Chairman

37 President Road Kellyville
NSW Australia 2155

Tel: +61298361669
Mob: +61404876694
Fax: +61298361669